Why GSK just inked a $330M deal with a Roivant subsidiary
GlaxoSmithKline (NYSE: GSK) and Roivant subsidiary Dermavant have inked a deal worth about $330 million.
Dermavant, which has a sizable presence at Roivant’s research and development-heavy outpost in Durham, has agreed to purchase the rights to GSK’s drug tapinarof – a treatment under development for psoriasis and atopic dermatitis – and its backup programs for an initial payment of about $20 0 million and future milestone payment of about $130 million.
“This was the result of a strategic…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Jennifer Henderson Source Type: news